KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Amortization - Intangibles (2019 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Amortization - Intangibles for 7 consecutive years, with $24.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Amortization - Intangibles rose 34.35% to $24.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $89.5 million, a 14.72% increase, with the full-year FY2025 number at $89.5 million, up 14.72% from a year prior.
  • Amortization - Intangibles was $24.6 million for Q4 2025 at Supernus Pharmaceuticals, up from $24.3 million in the prior quarter.
  • In the past five years, Amortization - Intangibles ranged from a high of $24.6 million in Q4 2025 to a low of $5.9 million in Q2 2021.
  • A 5-year average of $18.1 million and a median of $20.1 million in 2023 define the central range for Amortization - Intangibles.
  • Peak YoY movement for Amortization - Intangibles: surged 376.37% in 2021, then dropped 13.38% in 2024.
  • Supernus Pharmaceuticals' Amortization - Intangibles stood at $12.0 million in 2021, then soared by 72.39% to $20.7 million in 2022, then grew by 1.78% to $21.1 million in 2023, then fell by 13.38% to $18.3 million in 2024, then surged by 34.35% to $24.6 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Amortization - Intangibles are $24.6 million (Q4 2025), $24.3 million (Q3 2025), and $20.8 million (Q2 2025).